MONTREAL, CANADA -- (MARKET WIRE) -- January 11, 2007 -- ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") announced today that it has received regulatory approval from Health Canada for the expansion of its lead compound PBI-1402's clinical program to include the treatment of anemic patients with Chronic Kidney Disease (CKD).
